[ENTA] Enanta Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 34.53 Change: 1.51 (4.57%)
Ext. hours: Change: 0 (0%)

chart ENTA

Refresh chart

Strongest Trends Summary For ENTA

ENTA is in the medium-term up 29% in 1 month. In the long-term up 310% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Enanta Pharmaceuticals, Inc., a biotechnology company, is engaged in the development of small molecule drugs for the infectious disease field. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products comprising EDP-788 for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc.; and AbbVie Inc. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 36.42% Sales Growth - Q/Q-25.98% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA47.08% ROE51.63% ROI
Current Ratio8.98 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin82.62% Net Profit Margin64.48% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities2.26 M Cash From Investing Activities-100.46 M Cash From Operating Activities93.25 M Gross Profit
Net Profit28.75 M Operating Profit48.56 M Total Assets245.88 M Total Current Assets177.78 M
Total Current Liabilities19.79 M Total Debt180 K Total Liabilities21.67 M Total Revenue57.37 M
Technical Data
High 52 week126.37 Low 52 week65.41 Last close100.65 Last change1.01%
RSI77.21 Average true range5.2 Beta1.03 Volume182.38 K
Simple moving average 20 days11.85% Simple moving average 50 days26.12% Simple moving average 200 days10.71%
Performance Data
Performance Week-2.42% Performance Month33.29% Performance Quart25.7% Performance Half9.94%
Performance Year26.75% Performance Year-to-date42.1% Volatility daily3.38% Volatility weekly7.55%
Volatility monthly15.47% Volatility yearly53.58% Relative Volume295.56% Average Volume290.82 K
New High0.99% New Low

News

2019-03-18 07:30:00 | Enanta Pharmaceuticals Completes Enrollment in Two Ongoing Phase 2 Studies

2019-03-11 07:30:00 | Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences

2019-02-15 07:35:00 | Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit — New Research Emphasizes Economic Growth

2019-02-06 22:49:54 | Edited Transcript of ENTA earnings conference call or presentation 6-Feb-19 9:30pm GMT

2019-02-06 20:43:08 | Enanta Pharmaceuticals Inc ENTA Q1 2019 Earnings Conference Call Transcript

2019-02-06 17:10:10 | Enanta Pharmaceuticals ENTA Lags Q1 Earnings and Revenue Estimates

2019-02-06 16:07:13 | Enanta Pharmaceuticals: Fiscal 1Q Earnings Snapshot

2019-02-06 16:01:00 | Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2018

2019-01-30 10:31:03 | Enanta Pharmaceuticals ENTA Earnings Expected to Grow: Should You Buy?

2019-01-22 12:09:11 | Do You Like Enanta Pharmaceuticals, Inc. NASDAQ:ENTA At This P/E Ratio?

2019-01-22 08:00:00 | Enanta Pharmaceuticals to Host Conference Call on February 6th at 4:30 pm ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2018

2019-01-03 08:00:00 | Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Business Outlook for 2019 during the 37th Annual J.P. Morgan Healthcare Conference

2018-12-20 08:00:00 | Enanta Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

2018-12-15 11:23:55 | Here is What Hedge Funds Think About Enanta Pharmaceuticals Inc ENTA

2018-12-05 10:28:44 | Is Enanta Pharmaceuticals Inc’s NASDAQ:ENTA CEO Pay Fair?

2018-11-29 16:48:07 | Enanta Pharmaceuticals Inc ENTA Files 10-K for the Fiscal Year Ended on September 30, 2018

2018-11-29 00:11:44 | Edited Transcript of ENTA earnings conference call or presentation 26-Nov-18 9:30pm GMT

2018-11-26 19:34:33 | Enanta Pharmaceuticals Inc ENTA Q4 2018 Earnings Conference Call Transcript

2018-11-26 16:16:57 | Enanta Pharmaceuticals: Fiscal 4Q Earnings Snapshot

2018-11-26 16:01:00 | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018

2018-11-19 10:30:03 | Enanta Pharmaceuticals ENTA Expected to Beat Earnings Estimates: Should You Buy?

2018-11-13 11:40:00 | Enanta Announces that AbbVie’s MAVYRET™ glecaprevir/pibrentasvir Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis

2018-11-13 11:30:00 | AbbVie's MAVYRET™ glecaprevir/pibrentasvir Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis

2018-11-07 10:10:03 | Why the Earnings Surprise Streak Could Continue for Enanta Pharmaceuticals ENTA

2018-10-29 07:30:00 | Enanta Pharmaceuticals to Host Conference Call on November 26 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018

2018-10-26 08:15:00 | Report: Developing Opportunities within Assured Guaranty, Potbelly, Enanta Pharmaceuticals, Seagate Technology, Ctrip.com International, and CyberArk Software — Future Expectations, Projections Moving into 2018

2018-10-23 07:30:00 | Enanta Pharmaceuticals Announces Positive Phase 1 Results and Initiation of Phase 2a Clinical Study of EDP-938 for Respiratory Syncytial Virus

2018-10-11 13:31:41 | How Good Is Enanta Pharmaceuticals Inc NASDAQ:ENTA, When It Comes To ROE?

2018-10-05 11:00:00 | Liver Cancers Rising - Stocks to Watch

2018-09-25 08:45:00 | Recent Analysis Shows Enanta Pharmaceuticals, Multi-Color, Otter Tail, Franklin Resources, CubeSmart, and EnPro Industries Market Influences — Renewed Outlook, Key Drivers of Growth

2018-09-05 07:30:00 | Enanta Pharmaceuticals to Present New Data on its RSV Inhibitor EDP-938 at the 11th International Respiratory Syncytial Virus Symposium

2018-08-27 16:01:00 | Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences

2018-08-20 17:45:22 | Edited Transcript of ENTA earnings conference call or presentation 7-Aug-18 8:30pm GMT

2018-08-13 06:00:57 | Why Enanta Stock Is Still a Strong Buy With Huge Upside

2018-08-07 17:35:09 | Enanta Pharmaceuticals ENTA Q3 Earnings and Revenues Top Estimates

2018-08-07 16:32:22 | Enanta Pharmaceuticals: Fiscal 3Q Earnings Snapshot

2018-08-07 16:01:00 | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2018

2018-08-02 10:08:02 | Why Earnings Season Could Be Great for Enanta Pharmaceuticals ENTA

2018-07-16 07:30:00 | Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Third Quarter Ended June 30, 2018

2018-06-27 10:39:02 | Achieve Life Sciences' Shares Rise on Positive Clinical Data

2018-06-15 14:39:50 | 2 Stable and 2 Speculative Biotech Stocks to Buy

2018-06-12 07:30:00 | Enanta Pharmaceuticals Recognizes the 1st International NASH Day

2018-06-07 08:10:00 | Today's Research Reports on Stocks to Watch: Enanta Pharmaceuticals and Vascular Biogenics

2018-06-01 08:38:12 | Why Enanta Pharmaceuticals ENTA Could Shock the Market Soon

2018-06-01 07:30:00 | Enanta Pharmaceuticals to Present at the NASDAQ 38th Investor Conference Presentation to be Webcast on June 12 at 9:30 A.M. GMT

2018-05-29 17:45:09 | Bayer's Generic Competition, Pipeline Setback Issues Remain

2018-05-29 08:10:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Assembly Biosciences, MGP Ingredients, Globant S.A, 8point3 Energy Partners LP, Flexion Therapeutics, and Enanta Pharmaceuticals — New Research Emphasizes Economic Growth

2018-05-23 15:05:07 | Dr. Reddy's RDY Q4 Earnings Fall, Revenues Decline Y/Y

2018-05-21 14:00:23 | Analysing NVR, DPZ, ENTA And QLYS Stocks

2018-05-21 12:30:02 | Total Returns and Sector Exposure for Growth Indexes—Continued